• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Nuwellis Inc.

    6/12/25 4:26:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Nuwellis, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    67113Y603

    (CUSIP Number)


    06/09/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    BIGGER CAPITAL FUND L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    Bigger Capital Fund GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    District 2 Capital Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    District 2 Capital LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    District 2 GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    District 2 Holdings LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    239,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    239,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    239,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    67113Y603


    1Names of Reporting Persons

    Bigger Michael
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    478,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    478,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    478,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nuwellis, Inc.
    (b)Address of issuer's principal executive offices:

    12988 Valley View Road, Eden Prairie, MN 55344
    Item 2. 
    (a)Name of person filing:

    Bigger Capital Fund, LP ("Bigger Capital") Bigger Capital Fund GP, LLC ("Bigger GP") District 2 Capital Fund LP ("District 2 CF") District 2 Capital LP ("District 2") District 2 GP LLC ("District 2 GP") District 2 Holdings LLC ("District 2 Holdings") Michael Bigger Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    Bigger Capital Fund, LP 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135 Bigger Capital Fund GP, LLC 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135 District 2 Capital Fund LP 175 W. Carver Street Huntington, NY 11743 District 2 Capital LP 175 W. Carver Street Huntington, NY 11743 District 2 GP LLC 175 W. Carver Street Huntington, NY 11743 District 2 Holdings LLC 175 W. Carver Street Huntington, NY 11743 Michael Bigger 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135
    (c)Citizenship:

    Bigger Capital Fund, LP Delaware Bigger Capital Fund GP, LLC Delaware District 2 Capital Fund LP Delaware District 2 Capital LP Delaware District 2 GP LLC Delaware District 2 Holdings LLC Delaware Michael Bigger USA
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    67113Y603
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 9, 2025, Bigger Capital beneficially owned 239,000 shares of Common Stock. In addition, Bigger Capital beneficially owned 1,983,221 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation. The amount does not include shares issuable upon the exercise of Series A Warrants and Series B Warrants, the exercise of which are subject to shareholder approval and a 4.99% beneficial ownership limitation. Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the Issuer's securities described herein. Mr. Bigger, as the managing member of Bigger GP may be deemed to beneficially own the Issuer's securities described herein. As of June 9, 2025, District 2 CF beneficially owned 239,000 shares of Common Stock. In addition, District 2 CF beneficially owned 872,111 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation. The amount does not include shares issuable upon the exercise of Series A Warrants and Series B Warrants, the exercise of which are subject to shareholder approval and a 4.99% beneficial ownership limitation. District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the Issuer's securities described herein beneficially owned by District 2 CF. District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the Issuer's securities described herein beneficially owned by District 2 CF. District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the Issuer's securities described herein beneficially owned by District 2 CF. Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own the: (i) 239,000 shares of Common Stock beneficially owned by Bigger Capital, (ii) 1,983,221 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation owned by Bigger Capital, (iii) shares issuable upon exercise of Series A Warrants and Series B Warrants, the exercise of which are subject to shareholder approval and a 4.99% beneficial ownership limitation owned by Bigger Capital, (iv) 239,000 shares of Common Stock, beneficially owned by District 2 CF, (v) 872,111 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation owned by District 2 CF, and (vi) shares issuable upon exercise of Series A Warrants and Series B Warrants, the exercise of which are subject to shareholder approval and a 4.99% beneficial ownership limitation owned by District 2 CF. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by District 2 CF. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities. Prior to market open on June 11, 2025, the Reporting Persons sold the Common Stock, including the shares of Common Stock issuable upon exercise of Pre-Funded Warrants. The Series A Warrants and Series B Warrants are not exercisable as of the date hereof and are subject to a 4.99% beneficial ownership limitation.
    (b)Percent of class:

    The following percentages are based on 4,780,723 shares of Common Stock outstanding immediately after the offering based upon the Issuer's Prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission on June 10, 2025. As of June 9, 2025, each of Bigger Capital and Bigger GP may be deemed to beneficially own approximately 4.99% of the outstanding shares of Common Stock. Prior to market open on June 11, 2025, each of Bigger Capital and Bigger GP had no beneficial ownership due to: (i) the sale of 239,000 shares of Common Stock, (ii) the sale of 1,983,221 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation, and (iii) the requirement in the Series A Warrants and Series B Warrants that the exercise of such securities is subject to shareholder approval and a 4.99% beneficial ownership limitation. As of June 9, 2025, each of District 2 CF, District 2, District 2 GP and District Holdings may be deemed to beneficially own approximately 4.99% of the outstanding shares of Common Stock. Prior to market open on June 11, 2025, each of District 2 CF, District 2, District 2 GP and District Holdings had no beneficial ownership due to: (i) the sale of 239,000 shares of Common Stock, (ii) the sale of 872,111 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation, and (iii) the requirement in the Series A Warrants and Series B Warrants that the exercise of such securities is subject to shareholder approval and a 4.99% beneficial ownership limitation. As of June 9, 2025, Mr. Bigger may be deemed to beneficially own approximately 9.99% of the outstanding shares of Common Stock. Prior to market open on June 11, 2025, Mr. Bigger had no beneficial ownership due to: (i) the sale of 478,000 shares of Common Stock, (ii) the sale of 2,855,332 shares of Common Stock issuable upon exercise of Pre-Funded Warrants, which were subject to a 9.99% beneficial ownership limitation, and (iii) the requirement in the Series A Warrants and Series B Warrants that the exercise of such securities is subject to shareholder approval and a 4.99% beneficial ownership limitation. Regarding Item 5 below, prior to market open on June 11, 2025, the Reporting Persons sold all of their Common Stock and accordingly, the Reporting Persons as of June 11, 2025, are not the beneficial owners of at least 5.00% of the Issuer's Common Stock as the exercise of the Series A Warrants and Series B Warrants are subject to shareholder approval and a 4.99% beneficial ownership limitation.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIGGER CAPITAL FUND L P
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of Bigger Capital Fund GP, LLC, its general partner
    Date:06/12/2025
     
    Bigger Capital Fund GP, LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:06/12/2025
     
    District 2 Capital Fund LP
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of District 2 GP LLC, its general partner
    Date:06/12/2025
     
    District 2 Capital LP
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:06/12/2025
     
    District 2 GP LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:06/12/2025
     
    District 2 Holdings LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:06/12/2025
     
    Bigger Michael
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger
    Date:06/12/2025
    Exhibit Information

    99.1 - Joint Filing Agreement

    Get the next $NUWE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/30/24 4:11:06 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/2/24 4:12:11 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      5/6/24 4:01:02 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Nuwellis Inc.

      SCHEDULE 13G - Nuwellis, Inc. (0001506492) (Subject)

      6/12/25 4:26:02 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form EFFECT filed by Nuwellis Inc.

      EFFECT - Nuwellis, Inc. (0001506492) (Filer)

      6/10/25 12:15:13 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Nuwellis Inc.

      424B4 - Nuwellis, Inc. (0001506492) (Filer)

      6/9/25 9:44:26 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Nuwellis with a new price target

      ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

      7/29/24 7:42:07 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

      MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock ("Common Stock"), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995 shares of Common Stock and Series B Warrants to purchase up to 16,666,665 shares of Common Stock with gross proceeds of approximately $5.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase a

      6/10/25 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering

      MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock ("Common Stock"), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock. The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants, and the public o

      6/9/25 9:15:42 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Erb John L converted options into 1,100,022 shares (SEC Form 4)

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      6/11/25 8:43:36 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Mcdonald David

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      5/21/25 4:59:22 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Mccormick Michael Kendrick

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      5/21/25 4:50:29 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

      MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

      2/24/25 4:05:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces Board of Directors Transition

      MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

      11/1/23 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

      MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board

      6/5/23 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

      MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a

      4/22/25 4:04:59 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.Full year operating cost reduction of $5.9 million, or 26%, compared to the pr

      3/11/25 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care